Village Farms (VFF) Q1 2026 earnings review
Pure-Play Transition Complete, But Taxes Bite Cash Flow
Village Farms has officially shed its produce legacy, reorganizing into a unified cannabis operator. The top line looks great: consolidated net sales rose 27% year-over-year to $50.2M, driven entirely by a 171% explosion in international exports. Profitability is stabilizing, marking the fourth consecutive quarter of positive net income ($2.9M). However, the 'sustainably profitable' narrative took a hit on the cash flow statement. Operating cash flow reversed to a negative $11.8M due to a massive $15M Canadian tax payment. While management expects to rebuild cash through year-end, the reality of being a full cash taxpayer in Canada is now a structural headwind.
🐂 Bull Case
The EU-GMP certification moat is paying off. International medical exports hit a record $14.6M (up 171% YoY), proving VFF's dominance in Germany. With capacity expanding, this high-margin channel is a massive growth engine.
Cannabis gross margin expanded to 43% from 39% a year ago. Management is successfully shifting the mix away from low-margin domestic wholesale toward lucrative international and branded retail channels.
🐻 Bear Case
Having exhausted prior tax loss carryforwards, VFF is now a full cash taxpayer. A $15M Q1 tax payment drove operating cash flow to -$11.8M, proving that Canadian operations carry a heavy, inescapable cash burden.
The U.S. Cannabis segment continues to bleed, with sales down 20% YoY to $3.1M. State-level regulatory crackdowns on hemp-derived products are suffocating this division.
⚖️ Verdict: ⚪
Neutral. The operational pivot to a pure cannabis model is successful, and international demand is a proven driver. However, the reality of Canadian tax outflows limits true free cash flow generation, and upcoming capacity expansions carry execution risk.
Key Themes
International Exports Leading Growth
International medical export sales accelerated aggressively, jumping 171% year-over-year to $14.6M. Sequential growth was 60%, validating management's claim that demand for EU-GMP compliant products (especially in Germany) outstrips current supply. VFF currently boasts three of the top five leading cultivars in Germany.
Netherlands Operations Scaling Rapidly
Sales in the Netherlands accelerated 448% year-over-year to $2.66M. The company expects to commence operations at its Phase II facility in Q2 2026, aiming to ramp to a full 10-tonne annual capacity by year-end. This is a critical secondary growth pillar outside of Canada.
Margin Profile Elevating
Cannabis gross margin expanded to 43% from 39% a year ago, beating the company's long-term 30-40% target for the fourth consecutive quarter. This stable outperformance is driven by shifting volume toward premium international markets and better cost absorption at scaled facilities.
Cash Flow Contradicts Profitability Narrative
Despite management touting a 'sustainably profitable' enterprise with a 118% increase in Adjusted EBITDA to $9.9M, operating cash flow reversed dramatically. OCF fell to negative $11.8M (compared to +$2.9M last year). This was explicitly caused by $15.0M in Canadian income taxes paid in Q1. While net income is positive, true cash generation is severely hampered by tax obligations now that historical tax shields are gone.
U.S. Cannabis Segment Decelerating
The U.S. segment remains a clear laggard. Sales decelerated 20% year-over-year to $3.1M. The proliferation of unregulated products and confusing state-level legislative bans continue to shrink VFF's hemp-based revenues. This segment acts as dead weight on consolidated growth.
M&A Risk Signaling
CFO Steve Ruffini is stepping down to take a new role specifically focused on 'evaluating strategic M&A opportunities.' While management claims they will be 'prudent and patient,' dedicating a senior executive to acquisitions often precedes dilutive transactions or strategic distractions. This requires close monitoring given the company's limited cash reserves ($50M).
Macro: U.S. Schedule III Executive Order
Management explicitly cited President Trump's April 2026 executive order to immediately place FDA-approved marijuana products and state-regulated medical marijuana into Schedule III, with broader rescheduling hearings set for June 2026. VFF views this as a consequential macro catalyst that could rapidly open cross-border or U.S. domestic operational pathways.
Innovation: Pure Sunfarms Packaging & Strain Moat
The Pure Sunfarms brand has increased its dried flower market share for 15 consecutive months. Management attributes this acceleration to new packaging innovations that better showcase flower quality and aromas, proving that product presentation remains a critical differentiator in a crowded domestic retail market.
Other KPIs
Accelerating. Adjusted EBITDA jumped 118% year-over-year from $4.5M in 25Q1, representing a 20% margin on sales. This metric effectively demonstrates the core operating leverage of the cannabis business once produce operations are excluded.
Stable. Up 9% from $14.6M a year ago. While higher in absolute dollars, SG&A grew significantly slower than the 27% revenue growth, showing solid cost control and positive operating leverage.
Decelerating. Cash dropped sharply from $81.2M at the end of 2025. This $30M reduction was driven by the $11.8M operating cash burn, $9.2M in capital expenditures (facility upgrades), and $6.4M in share repurchases.
Guidance
Accelerating. Management expects the cash balance to grow from operating cash flow through the rest of 2026. This implies the Q1 tax-driven cash burn was a one-time seasonal shock and normal cash generation will resume in Q2-Q4.
Accelerating. The first half of the Delta 2 expansion is planted and will begin contributing to sales in Q2. Once fully completed in 2027, this will add 40 metric tonnes of capacity, expanding Canadian production by 33%.
Accelerating. Operations commence in Q2, stepping up to a 10-tonne annual run rate by the end of 2026. This represents a quintupling of total Netherlands production, setting up 2027 as a major revenue year for the European segment.
Key Questions
Canadian Tax Run-Rate
The $15M tax payment severely impacted Q1 cash flow. Is this a lump-sum annual payment for 2025 obligations, and what is the expected quarterly cash tax drag going forward now that legacy tax shields are exhausted?
M&A Strategy & Discipline
With the CFO transitioning specifically to evaluate M&A, what gaps exist in the current portfolio that require acquisitions? Given the ongoing capital needs for Delta 2 and the Netherlands, how will M&A be funded without diluting shareholders?
U.S. Operations vs Optionality
The U.S. hemp business declined 20% to just $3.1M. If the June 2026 Schedule III hearings result in favorable U.S. policy, does VFF plan to pivot its existing U.S. footprint entirely away from CBD/hemp toward THC, or maintain dual operations?